

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 11/2023

Date of preparation: **2023-05-22**

Abbreviated name of the Issuer: MABION S.A.

Subject matter:

Conclusion of an annex to the agreement for the supply of bioreactors to the Company's manufacturing facility

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 64/2021 of 30 November 2021 regarding the conclusion of an agreement with Adolf Kühner AG with its registered office in Switzerland ("Supplier") for the purchase of four bioreactors with a capacity of 2,500 litres each, together with additional services ("Agreement"), the Management Board of Mabion S.A. ("Company") hereby informs on entering into an annex to the Agreement ("Annex") on 22 May 2023.

Under the Annex, the parties agreed that the Supplier will manufacture and deliver two new bioreactors to the Company within a timeframe agreed for Q3 2023 (previously, the Agreement provided for the delivery of four bioreactors within 15 months from its date). With the Annex in place, the value of the Agreement has changed and amounts to EUR 1.8 million, and reflects additional services ordered by the Company (original amount: EUR 2.3 million). As a result, two new orbital shaking bioreactors will be installed at the Company to replace the two bioreactors used presently.

The Annex is a result of changes that the Company is implementing as a consequence of the adoption of the new Company Strategy for 2023–2027 whereof the Issuer informed in Current Report no. 7/2023 of 18 April 2023. In accordance with the Strategy, one of the objectives the Company is pursuing is to achieve diversification in bioreactor breeding technology.

Such bioreactor technology diversification is aimed at complementing the Company's development and process equipment with bioreactors employing conventional mixing technology. As a result of the above activities, Mabion will be able to offer services using both of these technologies. The resulting expanded panel of available bioreactor technologies will bring greater flexibility to the Company in discussions with future clients as part of the CDMO services offering, which should lead to greater business diversification, which the Management Board believes is one of the key factors for the Company's further growth.